Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is app...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Oncol
Glavni autori: Rossi, Ernesto, Maiorano, Brigida Anna, Pagliara, Monica Maria, Sammarco, Maria Grazia, Dosa, Tommaso, Martini, Maurizio, Rindi, Guido, Bria, Emilio, Blasi, Maria Antonietta, Tortora, Giampaolo, Schinzari, Giovanni
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2019
Teme:
Oncology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6460374/
https://ncbi.nlm.nih.gov/pubmed/31024839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00232
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items